Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04489732 · ClinicalTrials.gov registry record · Phase 1
MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer
A Phase 1 study of Xerostomia Following Radiotherapy, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT04489732 is a Phase 1 study of Xerostomia Following Radiotherapy that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04489732, a Phase 1 study of Xerostomia Following Radiotherapy, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center pilot study designed to determine the safety and tolerability of autologous bone marrow-derived Mesenchymal Stromal Cells (MSCs) in patients with xerostomia (dry mouth) after undergoing radiation therapy (XRT) for head and neck cancer (HNC). Up to 12 participants will be enrolled and can expect to be on study for up to 2 years.
Conditions Studied
Interventions
- BIOLOGICAL Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04489732
The ClinicalTrials.gov registry entry for NCT04489732 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Xerostomia Following Radiotherapy appearing as the primary indexed condition, and to 1 intervention - of which Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells is the first listed.
NCT04489732 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04489732 about?
NCT04489732 is a clinical study titled "MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer". This is a single center pilot study designed to determine the safety and tolerability of autologous bone marrow-derived Mesenchymal Stromal Cells (MSCs) in patients with xerostomia (dry mouth) after undergoing radiation therapy (XRT) for head and neck cancer (HNC). Up to 12 participants will be enro...
What is the current status of trial NCT04489732?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-02-18. Estimated completion is 2026-05.
What conditions does trial NCT04489732 study?
This clinical trial studies the following conditions: Xerostomia Following Radiotherapy.
What interventions are being tested in trial NCT04489732?
The interventions under investigation include: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04489732?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04489732 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.